<DOC>
	<DOCNO>NCT00038870</DOCNO>
	<brief_summary>1 . Determine feasibility generation autologous Acute Myelogenous Leukemia ( AML ) Chronic Myelogenous Leukemia myeloid blast crisis ( CML/BC ) derive dendritic cell activate lymphocyte ( DC/AL ) poor prognosis patient . 2 . Determine toxicity autologous leukemia derive dendritic cell activate lymphocyte ( DC/AL ) patient AML CML/BC . 3 . Quantitate circulate immune effector cell patient infusion DC/AL . 4 . Record efficacy AML CML/BC derive dendritic cell activate lymphocyte promote sustain remission patient AML CML/BC .</brief_summary>
	<brief_title>Therapy Relapsed AML With Chemotherapy Dendritic Cell Activated Lymphocytes</brief_title>
	<detailed_description>Most patient relapse AML either fail achieve second remission brief remission . Patients 60 year age histories antecedent hematological disorder , prior chemotherapy , poor risk cytogenetics generally short remission group two year survival le 10 % . Equally patient myeloid blast crisis CML often fail achieve remission response brief duration . Laboratory study show AML leukemic blast may induce culture differentiate dendritic cell turn may use activate autologous lymphocyte acquire leukemia specific cytotoxicity . This trial ass feasibility generation dendritic cell activate lymphocyte , toxicity efficacy activate cell give reinduction chemotherapy . Before study begin toxicity information generate trial similar cell give CML patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion : AML patient either first relapse diagnosis ) highrisk cytogenetics 7 , 5 , +8 , chromosome 9 11 abnormality , b ) WBC &gt; 50,000 , c ) age &gt; 60 years* . AML patient eligible cell collection &gt; 1000 circulate blasts/mm diagnosis . CML patient myeloid blast crisis &gt; 1000 circulate blasts/mm . Creatinine &lt; 2 , Bilirubin &lt; 3 . Age &gt; 18 . Exclusion : Factors would prevent patient receive cooperate full course therapy understanding informed consent procedure . Concurrent expect need therapy corticosteroid . Positive antibody human immunodeficiency virus I . Acute promyelocytic Leukemia ( FABM3 ) . History overt cardiac failure , systemic autoimmune disease expect need steroid therapy . Patients &gt; 60 eligible study find good prognosis cytogenetics ( inversion ( 16 ) ( 8 ; 21 ) ) subsequently withdraw study treat protocol without infusion autologous leukemia derive cell .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>Dendritic Cells</keyword>
</DOC>